Latest Conference Articles

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

FDA Green-Lights Elinzanetant, First Dual NK-1/NK-3 Antagonist, for Moderate to Severe Vasomotor Symptoms of Menopause

October 24th 2025

The Menopause Society Annual Meeting

The novel once-daily nonhormonal therapy offers a new option to offer women who prefer not to take HRT or for whom it is contraindicated.

Menopause: A Constellation of Syndromes Across 13 Body Systems

Menopause: A Constellation of Syndromes Across 13 Body Systems

October 24th 2025

The Menopause Society Annual Meeting

Our short slide show outlines interrelated syndromes of menopause across 13 body systems, implicating therapeutic targets and approaches for clinical practice.

Marla Shapiro, CM‎, MDCM, on Recognizing Early Perimenopause: Sleep, Mood, and Other Missed Clues

Marla Shapiro, CM‎, MDCM, on Recognizing Early Perimenopause: Sleep, Mood, and Other Missed Clues

October 24th 2025

The Menopause Society Annual Meeting

Subtle sleep, mood, and cycle changes may herald perimenopause. Dr. Marla Shapiro discusses how clinicians can recognize and address them early.

Menopause Education Lags in Residency Training Across Primary Care Specialties

Menopause Education Lags in Residency Training Across Primary Care Specialties

October 24th 2025

The Menopause Society Annual Meeting

Less than one-third of residents in IM, FM, and OB/GYN programs receive structured menopause training, leaving many unprepared for midlife women’s care.

Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease

Timing of Menopausal Hormone Therapy May Impact Biomarkers of Alzheimer Disease

October 24th 2025

The Menopause Society Annual Meeting

A secondary analysis of the ELITE trial suggests that there may be a postmenopausal "critical window" during which use of MHT is optimal.

Menopause Education Wholly Inadequate  for Physician Associates, According to New Survey Results

Menopause Education Wholly Inadequate for Physician Associates, According to New Survey Results

October 23rd 2025

The Menopause Society Annual Meeting

Only 3% of physician associate respondents reported receiving more than 5 hours of menopause-related training during their professional education.

Treating Hot Flashes May Improve Cognitive Symptoms: Study Author Explains the Connection

Treating Hot Flashes May Improve Cognitive Symptoms: Study Author Explains the Connection

October 23rd 2025

The Menopause Society Annual Meeting

TMS 2025: Katrina Wugalter, MA, explains why treating vasomotor symptoms may be key to improving cognitive function during menopause.

APOE ε4 and Inflammation Amplify Risk for Memory Decline in Women with Earlier Menopause

APOE ε4 and Inflammation Amplify Risk for Memory Decline in Women with Earlier Menopause

October 23rd 2025

The Menopause Society Annual Meeting

Earlier menopause, APOE ε4, and age-related inflammation combine to accelerate memory decline, revealing key factors in women’s Alzheimer disease risk.

Inequities in Menopause Care: How Provider and Patient Factors Combine to Limit Treatment

Inequities in Menopause Care: How Provider and Patient Factors Combine to Limit Treatment

October 23rd 2025

The Menopause Society Annual Meeting

TMS: Menopause care isn’t one-size-fits-all—and that’s the problem. Wake Forest data reveal deep disparities in who gets treated and how.

Donna Plecha, MD: Why You Should Start Breast Cancer Risk Assessment at Age 25

Donna Plecha, MD: Why You Should Start Breast Cancer Risk Assessment at Age 25

October 22nd 2025

The Menopause Society Annual Meeting

TMS 2025: Donna Plecha, MD, an expert in breast imaging, discusses essential breast cancer screening recommendations for primary care physicians.